Patients with a history of allergic reaction to irinotecan, cephalosporins or a severe penicillin allergy are not eligible
Prior allergic reaction to the hormones involved in this protocol
Prior allergic reaction to the study drug(s) involved in this protocol
Patients with a history of intolerance to trastuzumab (i.e. a grade  or  infusion reaction) are excluded; Note: patients with a history of mild infusion reaction to trastuzumab who have previously been successfully re-challenged after an infusion reaction with or without prophylactic medication are allowed
Previous allergic reaction to an immunomodulatory drug (IMiD)
Use of steroids for non-tumor indications (for example: asthma or severe allergic reaction) is permitted
Documented hypersensitivity reaction to any product with GSE
History of allergic reaction/hypersensitivity to temozolomide, dacarbazine, DSF or Cu.
History of allergic reaction to docetaxel
Any history of allergic reaction to chemotherapies used
History of allergic reaction to alpha--antitrypsin.
Patients with hypersensitivity or other allergic reaction to platinum chemotherapy.
Patients with hypersensitivity or other allergic reaction to taxanes.
Known allergic reaction to antibiotics of the aminoglycoside group (ie, streptomycin, gentamicin)
History of allergic reaction (including erythema nodosum) to lenalidomide
Allergic reaction to single-agent rucaparib or irinotecan
Prior allergic reaction or known intolerance to irinotecan
If in Arm G, significant allergic reaction to cisplatin.
Prior allergic reaction to cisplatin
Patients with a history of severe allergic reaction to cisplatin or carboplatin
Patient has had prior grade  infusion reaction to cetuximab
Documented allergic or acute hypersensitivity reaction attributed to antibody treatments
Prior allergic reaction to cisplatin
History of allergic reaction to interleukin- or nivolumab
History of a severe allergic reaction or anaphylactic reaction to a biological agent or history of hypersensitivity to any component of the trial drug (e.g., hypersensitivity or allergy to murine products).
The subject has a history of serious allergic reaction to any substance, resulting in hospitalization or requiring other emergent medical attention
History of allergic reaction to DSF or Cu
History of allergic reaction to natalizumab
Known serious allergic reaction to vandetanib or metformin
Prior allergic reaction to the study drug(s) involved in this protocol
Any allergic reaction to a previously administered monoclonal antibody or other therapeutic protein
Prior allergic reaction to temozolomide
Previous severe or life-threatening allergic reaction with rituximab or known allergy to the compounds found in INCB
Prior allergic reaction to the hormones involved in this protocol
Patients with known history of allergic reaction to intravenous (IV) contrast material that is not amenable to pre-treatment by University of Alabama at Birmingham (UAB) protocol
History of Grade  or higher allergic reaction with prior asparaginase treatment,
No prior known allergic reaction to monoclonal antibodies
History of >=  allergic reaction or any grade anaphylactic reaction during prior administration of tocilizumab
Subject has prior severe allergic reaction or intolerance to any component of mFOLFOX.
Previous allergic reaction to radioisotope bone tracers
Known history of serious allergic reaction including anaphylaxis or Stevens- Johnson syndrome/ toxic epidermal necrolysis
History of any hypersensitivity or allergic reaction to any beta lactam antibiotic, tazobactam, or any study therapy (IV or oral)
Patients with a prior hypersensitivity reaction to sargramostim
Prior allergic reaction or hypersensitivity to cetuximab or MEDI (durvalumab) or any of study drug excipients
Patients with a lifetime history of dermatitis as an allergic/toxic reaction to any medication
Prior allergic reaction to cetuximab
History of severe allergic reaction, including erythema nodosum, to lenalidomide
Prior known allergic reaction to pembrolizumab or its excipients
Prior allergic reaction to cisplatin
Prior allergic reaction to the study drug(s) involved in this protocol
Patients with previous hypersensitivity reaction to camptothecins are excluded
History of clinically significant allergic reaction attributed to any injected\n             compound.
Prior allergic reaction to any of the study drugs involved in this protocol
Prior allergic reaction to the study drug(s) involved in this protocol
Prior allergic reaction to the study drugs involved in this protocol or to a monoclonal antibody
Known contraindication to dexamethasone (allergic reaction or systemic fungal infection)
Known allergic reaction to any component of MEDI
Prior allergic reaction to cetuximab
History of significant adverse or allergic reaction to any component of G and, if enrolled in Part , anti-PD antibodies.
No prior allergic reaction or hypersensitivity to sulfonamides, celecoxib or NSAIDs
Patients must not have a known allergic reaction to epoetin alfa (Procrit) or human serum albumin
Prior allergic reaction to the study drugs.
Prior allergic reaction to the study drugs involved in this protocol
Known major adverse reaction/event in connection with previously made vaccination (e.g. asthma, anaphylaxis or other serious reaction)
Has prior allergic reaction to bevacizumab
History of allergic reaction to parenteral administered recombinant protein product
Prior allergic reaction to the study drugs (cisplatin, mitomycin, fluorouracil [FU]) involved in this protocol
Prior allergic reaction to the drugs involved in this protocol
Patients with history of allergic reaction to metformin
Patients with history of allergic reaction to minocycline or to any of the tetracyclines
Prior allergic reaction to temozolomide
Prior allergic reaction to -FU or oxaliplatin
Prior allergic reaction or hypersensitivity to sulfonamides (may be allowed per investigator discretion based on patient history), celecoxib or NSAIDs
History of allergic reaction or intolerance to statin treatment
History of an allergic reaction or intolerance to irinotecan
History of allergic reaction (including erythema nodosum) to lenalidomide
Prior allergic reaction or severe intolerance to either irinotecan or temozolomide
History of allergic reaction to docetaxel
History of allergic reaction to disulfiram
Prior serious infusion reaction to cetuximab
Prior allergic reaction to temozolomide.
Prior allergic reaction to the study drug (bevacizumab)
Known history of allergic reaction to cremophor/paclitaxel
Prior allergic reaction to trastuzumab for the treatment of metastatic breast cancer
Prior carboplatin or cisplatin hypersensitivity reaction
Prior allergic reaction to the study drugs involved in this protocol
History of allergic reaction to ATRA
History of allergic reaction to dasatinib
Patients who have previously been administered basiliximab or who have had an allergic reaction to basiliximab or one of its components in the past will be excluded
History of serious allergic reaction, including anaphylaxis and toxic epidermal necrolysis
History of allergic reaction to a structural compound or biological agent similar to TH-
Prior allergic reaction to the study drug(s) involved in this protocol
Patients with a prior serious infusion reaction to cetuximab
History of serious allergic reaction to yeast or yeast-derived products, including known or suspected hypersensitivity reaction to sargramostim;
History of severe (Grade  or ) allergic or hypersensitivity reaction to therapeutic antibodies that required discontinuation of therapy
History of severe (Grade  or ) allergic or hypersensitivity reaction to therapeutic antibodies that required discontinuation of therapy
Documented allergic or acute hypersensitivity reaction attributed to antibody treatments
History of an allergic reaction to Human Serum Albumin
History of severe allergic or hypersensitivity reaction to other therapeutic antibodies that required discontinuation of therapy
Prior confirmed allergic reaction (including moderate rash, dyspnea, wheezing, urticaria or other symptoms) attributed to the administration of either anthracyclines or other liposomally encapsulated drugs that required discontinuation of prior therapy.
Patients with known allergic reaction to lamivudine or tenofovir DF
Known allergic reaction to nickel
History of allergic reaction to ivabradine
Patients with a history of allergic reaction to ropivacaine or other local amide anesthetics
History of an allergic reaction or previous intolerance to transcutaneous electronic nerve stimulation
No history of (H/O) allergic reaction to iron therapy
Prior allergic reaction to memantine (memantine hydrochloride)
History of an allergic reaction or previous intolerance to transcutaneous electronic nerve stimulation or to latex
Patient with known allergic or hypersensitivity reaction to rHUPH or any hyaluronidase extracts
Allergic reaction to carbamazepine or oxcarbazepine (major histocompatibility complex, class I, B [HLA-B]*)
History of allergic or other adverse reaction to venlafaxine or SSRIs
Patients with a history of a severe allergic reaction (anaphylaxis)
History of severe allergic reaction to obinutuzumab
Allergic reaction to omeprazole
Allergic reaction to vitamin D
Allergic reaction to metformin
Patients with a known history of allergic reaction to ethanol, nitroglycerin, or citrate
Known allergic reaction to gadopentetate dimeglumine (Gd-DTPA)
History of reaction to ICG, iodides, or technetium radiocolloid
Patients with renal failure or history of allergic reaction to Gadavist will be excluded
Participants with multiple drug allergies, and/or subjects who have had an allergic reaction to any intravenous iron replacement product, or a known history of hypersensitivity to ferumoxytol
Known allergic reaction to diethylene triamine pentaacetic acid (Gd-DTPA)
Previous allergic reaction to contrast medium
Known allergic reaction to gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA)
Subjects with multiple drug allergies and/or subjects who have had an allergic reaction to any intravenous iron replacement product or a known history of hypersensitivity to ferumoxytol
Subjects with multiple drug allergies and/or subjects who have had an allergic reaction to any intravenous iron replacement product or a known history of hypersensitivity to ferumoxytol
History of severe allergic/hypersensitivity reaction or significant transfusion reaction.
Women with hypersensitivity to phenylmethane compounds, or a history of allergic reaction to iodides
History of allergic reaction to MR contrast media
